Company profile · Biotech & medical
Lotus Pharmaceutical
美時化學製藥股份有限公司 · 1795
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Lotus Pharmaceutical engages in the development, manufacturing, and commercialisation of novel and generic pharmaceuticals.[1]
The company's products cover oncology drugs, complex generics, 505(b)(2) products, new chemical entities, and biosimilars, with a global footprint of over 90 countries worldwide.[1]
It operates a globally integrated research, manufacturing, and commercial platform, with manufacturing facilities in Taiwan, the United States, and Korea, as well as research and development hubs in India and the United States.[1]
The company engages in the manufacture and retail sale of drugs and medicines.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$2.1bn | -22.5% | -22.8% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$401m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Lotus Pharmaceutical Co., Ltd. |
|---|---|
| Chinese name | 美時化學製藥股份有限公司 |
| Stock code | 1795 (TWSE) |
| Industry | Biotech & medical |
| Founded | 30 Jun 1966 |
| Listed | 16 Dec 2019 |
| Paid-in capital | NT$2.7bn |
| Chairman | Vilhelm Robert Wessman |
| President | Petar Antonov Vazharov |
| Headquarters | 17F., No.277, SongRen Rd., Xin'yi Dist. Taipei City 110, Taiwan |
| Website | http://www.lotuspharm.com.tw |
| Official business description | 西藥製造、零售 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Annual report 2025 (English), business scope · annual_report · retrieved 03 Nov 2026
- MOPS 公司基本資料 美時化學製藥股份有限公司 · mops · retrieved 03 Nov 2026
Using it at work? Join the team-plan waiting list